☰

add BTK clinical

rdmorin committed 2026-01-21 16:12:01 -0800 commit 4f45534d9b7aa9330fc754012ed5d8e72e9e0988

				BTK.md
			
          @@ -13,6 +13,10 @@ One study reported BTK mutations in approximately 7% of FL and 11% of transforme

           Driver mutations affecting this gene in FL/DLBCL have been experimentally demonstrated to cause a reduction or loss of function (LOF).[@huFollicularLymphomaassociatedBTK2021]

          +## Clinical Relevance

          +

          +The BTK inhibitor Imbruvica (Ibrutinib) had prior FDA approval for use in MCL and MZL which has since been [withdrawn](https://www.drugs.com/history/imbruvica.html) because *primary outcomes from the confirmatory Phase 3 studies studies were considered insufficient to support conversion to full approval.*

          +

           ## Relevance tier by entity

           [[include:tables/table1_BTK.md]]

...	...	@@ -13,6 +13,10 @@ One study reported BTK mutations in approximately 7% of FL and 11% of transforme
13	13
14	14	Driver mutations affecting this gene in FL/DLBCL have been experimentally demonstrated to cause a reduction or loss of function (LOF).[@huFollicularLymphomaassociatedBTK2021]
15	15
	16	+## Clinical Relevance
	17	+
	18	+The BTK inhibitor Imbruvica (Ibrutinib) had prior FDA approval for use in MCL and MZL which has since been [withdrawn](https://www.drugs.com/history/imbruvica.html) because primary outcomes from the confirmatory Phase 3 studies studies were considered insufficient to support conversion to full approval.
	19	+
16	20	## Relevance tier by entity
17	21
18	22	[[include:tables/table1_BTK.md]]